Big Pharma's Manufacturing Blueprint for the Future - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Big Pharma's Manufacturing Blueprint for the Future
The pharmaceutical majors continue rationalizing manufacturing capacity in established markets as they forge their manufacturing networks in biologics and emerging markets.


Pharmaceutical Technology
Volume 35, Issue 8, pp. 40-47

Other companies. Among other changes in Big Pharma manufacturing networks includes AstraZeneca's construction of a new $150-million manufacturing facility in the Kaluga region in Russia. In June 2011, the company also announced plans to establish a Predictive Science Center in St. Petersburg. In addition, AstraZeneca has established several partnerships with Russian development institutes, including the Skolkovo Innovation Centre and Russia Venture Company. In China, Eli Lilly is building a second manufacturing plant and dedicated diabetes research center. Earlier this year, Boehringer Ingelheim acquired the rights and substantially all the assets at Amgen's Fremont, California, development and manufacturing facility. The Fremont site includes a 100,000-ft2 manufacturing facility with a pilot plant and process-development laboratories. Boehringer Ingelheim will use the facility to enhance its contract-manufacturing activities. The company has been a contract manufacturer for Amgen.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here